Asset Details
Do you wish to reserve the book?
Safety of Initiating Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure or Type 2 Diabetes and a History of Urinary Tract Infections
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety of Initiating Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure or Type 2 Diabetes and a History of Urinary Tract Infections
Do you wish to request the book?
Safety of Initiating Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure or Type 2 Diabetes and a History of Urinary Tract Infections
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety of Initiating Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure or Type 2 Diabetes and a History of Urinary Tract Infections
2026
Overview
Background: Despite being a pillar of heart failure (HF) management, the guideline-directed initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) may be challenging due to the barrier of associated urinary tract infections (UTIs). Although there is a known risk, it remains unclear whether UTI incidence differs between patients with and without a prior history of UTIs. Methods: This study aimed to evaluate the risk–benefit profile of initiating an SGLT2i in patients with a history of UTIs. This retrospective, single-center healthcare system cohort analysis included adult patients hospitalized and taking an SGLT2i between 1 January 2020, and 31 August 2024. The included patients were divided into two cohorts: patients with and without a history of UTI pre-SGLT2i (described in this study as UTI-naive). Patients with urogenital structural abnormalities, indwelling catheters, or high-risk profiles were excluded. The primary outcome was the incidence of UTIs post-SGLT2i initiation. Secondary outcomes included the number of UTIs within 30, 60, and 90 days after starting an SGLT2i. Results: A total of 280 patients were evaluated for this study, of which 250 were included for analysis. Of those, 197 were UTI-naive, and 53 had a history of UTI pre-SGLT2i use. The most utilized SGLT2i was empagliflozin (75.6%). Amongst the cohorts, 20.4% of the UTI-naive patients developed a UTI post-SGLT2i versus 30.2% in patients with a historical UTI (p = 0.13). Conclusions: There was no significant difference in UTIs developed up to 90 days post-SGLT2i initiation, regardless of previous infections, suggesting that a history of UTI should not be a barrier to differing first-line therapy.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
We currently cannot retrieve any items related to this title. Kindly check back at a later time.